| __timestamp | Amphastar Pharmaceuticals, Inc. | BioCryst Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 40373000 | 7461000 |
| Thursday, January 1, 2015 | 46974000 | 13047000 |
| Friday, January 1, 2016 | 47298000 | 11253000 |
| Sunday, January 1, 2017 | 50918000 | 13933000 |
| Monday, January 1, 2018 | 58044000 | 29514000 |
| Tuesday, January 1, 2019 | 63109000 | 37121000 |
| Wednesday, January 1, 2020 | 65157000 | 67929000 |
| Friday, January 1, 2021 | 68920000 | 118818000 |
| Saturday, January 1, 2022 | 66592000 | 159371000 |
| Sunday, January 1, 2023 | 80393000 | 213894000 |
Cracking the code
In the competitive landscape of pharmaceuticals, understanding the financial dynamics of companies is crucial. Over the past decade, Amphastar Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Amphastar's SG&A expenses grew by approximately 99%, peaking in 2023. In contrast, BioCryst's expenses surged by an astounding 2,765% during the same period, reflecting its aggressive expansion and strategic investments.
Amphastar maintained a steady growth trajectory, with expenses increasing by about 65% from 2014 to 2019, before a sharper rise in the following years. Meanwhile, BioCryst's expenses skyrocketed, particularly from 2020 onwards, indicating a shift in operational strategy. This financial evolution highlights the differing approaches of these two industry players, offering insights into their strategic priorities and market positioning.
Cost Management Insights: SG&A Expenses for Viatris Inc. and BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Exelixis, Inc. vs BioCryst Pharmaceuticals, Inc.
SG&A Efficiency Analysis: Comparing Jazz Pharmaceuticals plc and Amphastar Pharmaceuticals, Inc.
Veracyte, Inc. or BioCryst Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Operational Costs Compared: SG&A Analysis of ACADIA Pharmaceuticals Inc. and BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for MorphoSys AG and Amphastar Pharmaceuticals, Inc.
Comparing SG&A Expenses: HUTCHMED (China) Limited vs Amphastar Pharmaceuticals, Inc. Trends and Insights
SG&A Efficiency Analysis: Comparing Arrowhead Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.
ImmunityBio, Inc. vs BioCryst Pharmaceuticals, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Supernus Pharmaceuticals, Inc. vs Amphastar Pharmaceuticals, Inc. Trends and Insights
Who Optimizes SG&A Costs Better? Dynavax Technologies Corporation or BioCryst Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Travere Therapeutics, Inc. vs BioCryst Pharmaceuticals, Inc.